Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 3/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28798142 | 0.96 | MAOB (0.42) | MAOBMAOATAAR1DPP4HTR2A | |
| SCHEMBL27889476 | 0.96 | MAOB (0.42) | MAOBMAOATAAR1DPP4HTR2A | |
| SCHEMBL42288 | 0.96 | MAOB (0.42) | MAOBMAOATAAR1DPP4HTR2A | |
| Methylamine SCHEMBL28201991 | 0.86 | MEN1 (0.33) | MAOBMAOATAAR1DPP4 | |
| SCHEMBL28682799 | 0.83 | MAOB (0.34) | MAOBMAOATAAR1 | |
| SCHEMBL27501736 | 0.82 | TSHR (0.35) | MAOBMAOATAAR1 | |
| Ethane SCHEMBL27995166 | 0.81 | MEN1 (0.34) | — | |
| SCHEMBL28931899 | 0.79 | SLC6A3 (0.42) | MAOBMAOATAAR1SLC6A4SLC6A3 | |
| SCHEMBL12466046 | 0.79 | SLC6A4 (0.42) | MAOBMAOATAAR1SLC6A4SLC6A3 | |
| SCHEMBL28678419 | 0.79 | MEN1 (0.35) | TAAR1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| CN-116327950-A | Use of a composition for the treatment of neuropsychiatric symptoms of neurodegenerative diseases | 阿泽范药品公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116139282-A | Compositions and methods for treating neurodegenerative diseases | 阿泽范药品公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | AZEVAN PHARMACEUTICALS INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-11628160-B2 | Compositions and methods for treating brain injury | AZEVAN PHARMACEUTICALS, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| CN-106459021-B | Compositions and methods for treating neurodegenerative diseases | 阿泽范药品公司 | 2023-04-07 | — | — | CN | disclosed |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-10953001-B2 | Methods for treating post traumatic stress disorder | AZEVAN PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3351104-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF INTERMITTENT EXPLOSIVE DISORDER | AZEVAN PHARMACEUTICALS INC (US) | 2020-12-09 | — | — | EP | disclosed |
| US-20200276167-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS INC (US) | 2020-09-03 | — | — | US | disclosed |
| WO-2015148962-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | AZEVAN PHARMACEUTICALS, INC. (US) | 2015-10-01 | — | — | WO | disclosed |
| CN-104922117-A | BETA-LACTAMYLALKANOIC ACIDS FOR TREATING PREMENSTRUAL DISORDERS | AZEVAN PHARMACEUTICALS INC | 2015-09-23 | — | — | CN | disclosed |
| EP-2587919-A1 | METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER | Azevan Pharmaceuticals, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130109666-A1 | METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER | AZEVAN PHARMACEUTICALS, INC. (US) | 2013-05-02 | — | — | US | disclosed |
| WO-2012003436-A1 | METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER | AZEVAN PHARMACEUTICALS, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| US-20090170825-A1 | BETA-LACTAMYLALKANOIC ACIDS FOR TREATING PREMENSTRUAL DISORDERS | AZEVAN PHARMACEUTICALS, INC. | 2009-07-02 | — | — | US | disclosed |
| CN-101208010-A | Beta-lactamylalkanoic acids for the treatment of premenstrual disorders | AZEVAN PHARMACEUTICALS INC (US) | 2008-06-25 | — | — | CN | disclosed |
| EP-1868434-A2 | BETA-LACTAMYLALKANOIC ACIDS FOR TREATING PREMENSTRUAL DISORDERS | Azevan Pharmaceuticals, Inc. (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006102308-A2 | BETA-LACTAMYL VASOPRESSIN V1B ANTAGONISTS | AZEVAN PHARMACEUTICALS, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006102283-A2 | BETA-LACTAMYLALKANOIC ACIDS FOR TREATING PREMENSTRUAL DISORDERS | AZEVAN PHARMACEUTICALS, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | MAOB 217/4885MAOA 313/4885TAAR1 3840/4885 |
| US-10953001-B2 | Methods for treating post traumatic stress disorder | GPX4, CRH, TXN | MAOB 248/4885MAOA 423/4885TAAR1 399/4885 |
| US-20200276167-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | MAOB 217/4885MAOA 313/4885TAAR1 3840/4885 |
| US-20090170825-A1 | BETA-LACTAMYLALKANOIC ACIDS FOR TREATING PREMENSTRUAL DISORDERS | GABBR1, GABBR2, ALAD | MAOB 574/4885MAOA 770/4885TAAR1 2796/4885 |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | MAOB 247/4885MAOA 240/4885TAAR1 173/4885 |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, AVPR2, AVPR1B | MAOB 247/4885MAOA 240/4885TAAR1 173/4885 |
| US-11628160-B2 | Compositions and methods for treating brain injury | FABP7, PYGB, CHAT | MAOB 217/4885MAOA 313/4885TAAR1 3840/4885 |
| US-20130109666-A1 | METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER | GPX4, CRH, TXN | MAOB 248/4885MAOA 423/4885TAAR1 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.